Improving the efficacy of antibody-based cancer therapies

被引：639

作者：

Carter, P ^{[1
]}

机构：

[1] Immunex Corp, Seattle, WA 98101 USA

来源：

NATURE REVIEWS CANCER | 2001年 / 1卷 / 02期

关键词：

D O I：

10.1038/35101072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies.

引用

页码：118 / 129

页数：12

共 140 条

[1] Adams GP, 2001, CANCER RES, V61, P4750
[2] Adams GP, 1998, CANCER RES, V58, P485
[3] ADAMS GP, 1993, CANCER RES, V53, P4026
[4] A potential role for activated HER-2 in prostate cancer
Agus, DB
Akita, RW
Fox, WD
Lofgren, JA
Higgins, B
Maiese, K
Scher, HI
Sliwkowski, MX
[J]. SEMINARS IN ONCOLOGY, 2000, 27 (06) : 76 - 83
[5] Ajani JA, 2000, CANCER J, V6, P78
[6] BAKER TS, 1994, ANTIGEN ANTIBODY MOL
[7] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast
Baselga, J
Tripathy, D
Mendelsohn, J
Baughman, S
Benz, CC
Dantis, L
Sklarin, NT
Seidman, AD
Hudis, CA
Moore, J
Rosen, PP
Twaddell, T
Henderson, IC
Norton, L
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 737 - 744
[8] Baselga J, 1998, CANCER RES, V58, P2825
[9] Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library
Begent, RHJ
Verhaar, MJ
Chester, KA
Casey, JL
Green, AJ
Napier, MP
HopeStone, LD
Cushen, N
Keep, PA
Johnson, CJ
Hawkins, RE
Hilson, AJW
Robson, L
[J]. NATURE MEDICINE, 1996, 2 (09) : 979 - 984
[10] Immunoliposomes - A promising approach to targeting cancer therapy
Bendas, G
[J]. BIODRUGS, 2001, 15 (04) : 215 - 224

← 1 2 3 4 5 6 7 8 9 10 →